Work

Results of A Phase I Study of Milatuzumab, a Humanized Anti-CD74 Antibody, and Veltuzumab, a Humanized Anti-CD20 Antibody, In Patients with Relapsed and Refractory B-Cell Non-Hodgkin's Lymphoma,

Year: 2011

Type: article

Study design: Clinical Trial

Source: Blood

DOI: 10.1182/blood.v118.21.3707.3707

Authors: Beth Christian, Lapo Alinari, Jeffrey A. Jones, Don M Benson, Joseph M. Flynn, Pierluigi Porcu, Mark E Lustberg, Mitchell Phelps, Ming Poi, Diana Chung, Carl Quinion, John C. Byrd, William Wegener, David M Goldenberg, Robert A. Baiocchi, Kristie A. Blum

Institutions: The Ohio State University, Immunomedics (United States), Center for Molecular Medicine and Immunology

Language: English

Topic: Lymphoma Diagnosis and Treatment

Subfield: Pathology and Forensic Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4252257778

FWCI: 0.224

Cites:

Cited by: 1

Related to: 10